PharmacovigilanceOfficial

AIFA: Italian public pharmaceutical spending reaches €9.04bn in January–April 2026

🇮🇹 AIFA · Fri 06 Nov 2026

AIFA's monitoring report puts public drug expenditure at 19.26% of the national health fund for the first four months of 2026, based on a provisional fund value.

Italy's medicines agency AIFA has published its monitoring report on pharmaceutical expenditure for January to April 2026. Total public spending, covering convenzionata (retail reimbursed prescriptions), direct purchases and oxygen, came to €9,036.9 million.

AIFA states that this equals 19.26% of the national health fund (Fondo Sanitario Nazionale, FSN). The percentage is calculated against the provisional 2026 FSN value communicated by the Ministry of Health, so it may change if that figure is revised.

The material available to VigiEye gives only the headline totals and the FSN ratio. It does not include a breakdown between the three spending components or a comparison with the same period of 2025, so no conclusions can be drawn here on trends or on any overshoot of spending ceilings.

For context, AIFA's periodic monitoring reports track spending against the ceilings set for Italy's pharmaceutical budget. The report has no direct pharmacovigilance or safety implications.

What it means for your team

  • Market-access teams can use the 19.26% FSN ratio as a reference point for the pressure on Italian pharmaceutical budgets in 2026.
  • The ratio rests on a provisional FSN value from the Ministry of Health, so it should be treated as subject to revision.
  • Teams should consult the full AIFA report for the split between convenzionata, direct purchases and oxygen before drawing conclusions on ceiling compliance or pricing and payback exposure.
  • Pharmacovigilance and quality teams need take no action; this is a spending indicator only.

Official source: AIFA ↗

Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.

More Pharmacovigilance All →